These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15308726)

  • 1. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
    Publicover J; Ramsburg E; Rose JK
    J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.
    Publicover J; Ramsburg E; Rose JK
    J Virol; 2005 Nov; 79(21):13231-8. PubMed ID: 16227246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.
    Ramsburg E; Publicover J; Buonocore L; Poholek A; Robek M; Palin A; Rose JK
    J Virol; 2005 Dec; 79(24):15043-53. PubMed ID: 16306575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.
    Cooper D; Wright KJ; Calderon PC; Guo M; Nasar F; Johnson JE; Coleman JW; Lee M; Kotash C; Yurgelonis I; Natuk RJ; Hendry RM; Udem SA; Clarke DK
    J Virol; 2008 Jan; 82(1):207-19. PubMed ID: 17942549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
    Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
    J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    Rose NF; Roberts A; Buonocore L; Rose JK
    J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
    Haglund K; Forman J; Kräusslich HG; Rose JK
    Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.
    Fang X; Zhang S; Sun X; Li J; Sun T
    Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.
    Rabinovich S; Powell RL; Lindsay RW; Yuan M; Carpov A; Wilson A; Lopez M; Coleman JW; Wagner D; Sharma P; Kemelman M; Wright KJ; Seabrook JP; Arendt H; Martinez J; DeStefano J; Chiuchiolo MJ; Parks CL
    PLoS One; 2014; 9(9):e106597. PubMed ID: 25215861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
    Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.
    Simon ID; Publicover J; Rose JK
    J Virol; 2007 Feb; 81(4):2078-82. PubMed ID: 17151110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.
    Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
    J Virol; 2002 Mar; 76(6):2730-8. PubMed ID: 11861840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
    Kapadia SU; Simon ID; Rose JK
    Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.